Fig. 3From: Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide studyCrude cumulative incidence plot for the events of hospitalisation for heart failure, composite MACE endpoint (myocardial infarction, stroke, or cardiovascular death), and all-cause mortality. GLP-1 glucagon like peptide-1 receptor agonist, SGLT Sodium–glucose transporter 2 inhibitor, DPP-4 dipeptidyl peptidase 4 inhibitorBack to article page